Scientists test if new brain cancer drugs reach their target
NCT ID NCT05798507
Summary
This early study aims to see if two new oral drugs, defactinib or VS-6766, can reach brain tumors in patients with glioblastoma. Researchers will give a single dose to 14 patients before their scheduled tumor removal surgery. The main goals are to measure how much drug gets into the tumor and surrounding brain tissue and to check for safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.